The company plans to meet with the FDA about an accelerated filing strategy and is preparing a Biologics License Application (BLA) submission for the first half of 2027. It also scheduled a webcast for 7:45 a.m. Eastern.
We covered the setup on November 13, when SELLAS narrowed the readout to this month: SELLAS Puts a November Date on Its REGAL Readout.
The +7% Headline Came Before the News Did
Several outlets and posts described SLS as up about 7% premarket on the results. The timing doesn't support that. Cboe's halt list shows Nasdaq halted SLS at 6:55 a.m. Eastern with the reason "News pending," and a resumption quote time of 7:25 a.m. Yahoo Finance showed $8.00, up 7.10% from Monday's $7.47 close, but that print was stamped 6:54:58 a.m., before the halt and before the release crossed. Reuters later withdrew a 7:11 a.m. alert that said SLS was up 7%, because the stock was halted at the time (MarketScreener).
Update, 6:20 AM PT: After trading resumed, SLS gapped far higher. StockAnalysis listed it at $27.10, up about 263%, on roughly 19.5 million premarket shares, and StockMarketWatch showed about $26.65, up about 257%, around 9:00 a.m. Eastern. Premarket prices are thin and can change quickly before the 9:30 a.m. open, and options don't trade until then.
Our math, not a forecast: a print near $27 is more than double the roughly $11.60 upper break-even of the Nov 20 straddle discussed below, and it sits close to the Jan 15, 2027 $30 call strike, the large open-interest line in the table below. Short calls and the short side of put trades that looked far out of the money on Monday would be deep in the money at that price.
A Small, Open-Label Trial With a p-Value Under 0.05
The result cleared the bar, but the details are what analysts will pick apart on the webcast:
None of that changes the topline result. It does explain why biotech traders often see a wide range of reactions to a "met primary endpoint" headline, and why the regulatory path (an accelerated filing, then an FDA review) still carries its own risk.
A 55% Straddle and a 535 IV30 Going In
Cboe's delayed quotes from Monday's close show how extreme the pricing was. The SLS Nov 20 $7.50 call was $1.90 / $2.20 and the $7.50 put was $1.90 / $2.20. That puts the at-the-money straddle at about $4.10 using midpoints, or roughly 55% of the $7.47 close, with break-evens near $3.40 and $11.60 by Friday. Near-the-money Nov 20 implied volatility was roughly 650% to 690%, and 30-day IV (IV30) was about 535, up from the roughly 336 we noted on November 13.
Our math, not a forecast: that pricing means the event premium was huge. If implied volatility collapses once the stock reopens, long options can lose much of their extrinsic value even if the stock moves sharply. Short options, meanwhile, face the risk of a gap far beyond any strike, whichever way it goes.
Puts Outnumbered Calls 3 to 1 Monday, but the Open Interest Leans the Other Way
Monday's session showed a lot of downside hedging: about 96,900 puts against 29,200 calls traded. Standing open interest still leaned toward calls, at about 676,000 calls vs. 346,000 puts.
| SLS contract | Monday volume | Open interest | Bid / Ask at close |
The Dec 18 and Dec 4 $6 puts each traded about as many contracts as their open interest. That pattern suggests mostly new positions opened Monday, though volume alone doesn't show whether they were bought or sold. The Jan $30 calls, at four times Monday's close, are the chain's largest open-interest line in that table and represent long-dated upside bets or overwrites.
Spreads Wide Enough to Drive a Truck Through
For background, see our implied volatility explainer and the OCC options disclosure document.
Sources
*By the OptionsPilot Editorial Team. Published November 17, 2026, 5:15 AM PT; updated 6:20 AM PT. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*